Regeneron price target raised to $915 from $860 at Wells Fargo

Wells Fargo analyst Mohit Bansal raised the firm’s price target on Regeneron to $915 from $860 and keeps an Overweight rating on the shares. The firm thinks COPD could be a $3.5B incremental opportunity for Dupi as a 30% reduction in events and corroborating secondaries is a solid profile for first approved biologic in this indication, the analyst tells investors in a research note.